BioHarvest Sciences Inc. files Form 6-K current reports as a foreign issuer, with exhibits that document company announcements and material changes. These filings cover the company's Botanical Synthesis platform, its VINIA-branded nutraceutical products, CDMO activities for plant-based compounds, earnings-call announcements, and business updates.
The filing record also includes governance and capital-structure subjects such as board composition changes, executive leadership transitions, long-term incentive awards, stock options, restricted share units, and equity incentive plan activity. Together, the disclosures provide formal records of BioHarvest's operating focus, public-company governance, compensation structure, and recurring communications to the market.
BioHarvest Sciences Inc. (BHST) filed a Prospectus Supplement enabling the resale of up to 461,538 common shares by a selling shareholder. The company is not selling any securities and will not receive proceeds from these sales; the selling holder will receive all net proceeds, while the company covers registration expenses.
The registered shares were issued upon conversion of the holder’s Convertible Notes on September 19, 2025 at USD 6.50 per share. The selling shareholder may dispose of shares on Nasdaq or via private transactions at market, fixed, related, varying, or negotiated prices through ordinary brokerage transactions as described under Plan of Distribution.
BioHarvest’s common shares trade on Nasdaq under “BHST.” The last reported sale price was USD 12.03 on October 14, 2025. Company common shares to be outstanding after this offering are stated as 19,593,267.
BioHarvest Sciences Inc. filed a Form D reporting a Regulation D, Rule 506(b) exempt equity offering with total proceeds of $401,348, all of which have been sold and $0 remaining. The notice shows the first sale occurred on 2025-09-19 and reports 2 total investors, with a stated $0 in sales commissions and finders' fees. The issuer is a corporation organized in British Columbia, Canada and identifies multiple executive officers and directors at its Vancouver address. The offering was not conducted as part of a business combination, the issuer does not intend the offering to last more than one year, and no proceeds are disclosed as paid to officers, directors, or promoters.
BioHarvest Sciences Inc. (BHST) discloses an extensive set of business and financial risks in this prospectus supplement, emphasizing the company's negative operating cash flow and concerns about its ability to continue as a going concern. The filing lists the need for additional capital, reliance on key inputs and e-commerce channels (VINIA.com, VINIA.co.il and Amazon Marketplace), potential subscription volatility, regulatory and manufacturing compliance risks, clinical trial enrollment risks for nutraceutical/cosmeceutical products, intellectual property and patent expiration risks, possible dilution from future financings, and uncertainty about a liquid trading market for the common shares.